To evaluate the functional outcomes in shoulder impingement syndrome treated with arthroscopic subacromial decompression and platelet rich plasma (PRP) augmentation

Evaluation of functional outcomes in shoulder impingement syndrome treated with arthroscopic subacromial decompression and platelet rich plasma (PRP) augmentation - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/04/066159

Enrollment

Registered

2024-04-23

Start date

Unknown

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M249- Joint derangement, unspecified

Interventions

Intervention1: Evaluation of functional outcomes in shoulder impingement syndrome treated with arthroscopic subacromial decompression and platelet rich plasma (PRP) augmentation: Evaluation of functio

Eligibility

Inclusion criteria

Inclusion criteria: The inclusion criteria will be skeletally mature patients with shoulder pain lasting for atleast 3 months with clinical diagnosis of shoulder impingement syndrome confirmed with MRI scan.

Exclusion criteria

Exclusion criteria: 1. Radicular pain. 2. Presence of pathologies such as frozen shoulder, calcific tendinitis, biceps subluxation, and a superior labrum anterior posterior lesion. 3. Previous shoulder surgery within last 6 months. 4. Connective tissue disorders such as rheumatoid arthritis, polymyalgia rheumatica, or fibromyalgia. 5. Full thickness rotator cuff tear on MRI. 6. Ligamentous laxity (positive sulcus test) or shoulder dislocation (positive apprehension test). 7. Prior corticosteroid injection within 3 months of the study. 8. Haemotological and bleeding diathesis.

Design outcomes

Primary

Measure	Time frame
Outcome will be assessed during follow up period as per VAS Score, Constant Score, UCLA Score.Timepoint: Outcome will be assessed during follow up period as per VAS Score, Constant Score, UCLA Score at 3 week, 3 months and 6 months	—

Secondary

Measure	Time frame
Any kind of skin reaction, pain and complication will be noted during follow up period.Timepoint: Any kind of skin reaction, pain and complication will be noted during follow up period of 3 week, 3 months and 6 months	—

Countries

India

Contacts

Public ContactDr Vikrant Khatkar

Pt.B.D.Sharma PGIMS Rohtak, Haryana

vikrant.khatkar.vk@gmail.com7015596834

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026